Presentation | Real-World Impact of GLP1-Based Therapies in CKM Syndrome
Population
Glucagon-Like Peptide-1 Receptor Agonists versus Metformin for Glycemic Control and Cardiovascular Risk Reduction in Adults with Prediabetes and Obesity
Vinicius de Sousa Barzon Serra, Mayo Clinic, Scottsdale, AZ; Ramzi Ibrahim, Mayo Clinic, Phoenix, AZ; Julia Zanco, Mayo Clinic, Scottsdale, AZ; Allah Dad, Abdelrahman Hafez, Hoang Nhat Pham, Juan Farina, Mayo Clinic, Phoenix, AZ; Steven Lester, Mayo Clinic Scottsdale, Scottsdale, AZ; Said Alsidawi, Hari P Chaliki, Chadi Ayoub, Luis R. P. Scott, Reza Arsanjani, Mayo Clinic, Scottsdale, AZ
